Merck KGaA, Darmstadt

Company snapshot

Merck KGaA, Darmstadt maintains 63 tracked programs across Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus, Solid Tumors, Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Pneumococcal Infections, HIV-1 Infection, Non-alcoholic Fatty Liver Disease, Metastatic Non Small Cell Lung Cancer, Chronic Heart Failure With Reduced Ejection Fraction

• 21 approved product(s) across US/EU regulatory metadata.
• 63 active pipeline program(s) linked via ClinicalTrials.gov.
• 63 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Merck KGaA, Darmstadt. Not investment advice.

• approval Jun 6, 2026

  Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

• Peer + 0 momentum

  Novartis India

  TA overlap score 50

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  BioNTech SE

  TA overlap score 24.6

• Peer + 0 momentum

  Eisai

  TA overlap score 24.4

• Peer + 0 momentum

  Vaccinex

  TA overlap score 22.2

• Peer + 0 momentum

  Serana Europe

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Merck KGaA, Darmstadt.

1. Jun 8, 2026 Clinical update

   Teriflunomide — Phase 3

2. Jun 8, 2026 Clinical update

   Pembrolizumab/Vibostolimab coformulation — Phase 2

3. Jun 8, 2026 Clinical update

   Pembrolizumab — Phase 2

4. Jun 8, 2026 Clinical update

   Pembrolizumab (K) — Phase 3

5. Jun 8, 2026 Clinical update

   Pembrolizumab (+) Berahyaluronidase alfa — Phase 2

View all clinical trial activity →

• What is Merck KGaA, Darmstadt?

  Merck KGaA, Darmstadt is a pharma organization headquartered in Darmstadt, DE. Primary therapeutic focus areas include Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus, Solid Tumors, Non-small Cell Lung Cancer. NovaPharmaNews links

• Is Merck KGaA, Darmstadt publicly traded?

  Merck KGaA, Darmstadt appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Merck KGaA, Darmstadt develop or market?

  We link 50 drug profile(s) where Merck KGaA, Darmstadt is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/merck-serono-europe-limited#company-drugs.

• What are the latest developments for Merck KGaA, Darmstadt?

  In the last 12 months our linked public records show 63 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Merck KGaA, Darmstadt focus on?

  Merck KGaA, Darmstadt focuses on Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus based on our analysis of their pipeline programs and drug development activities.